Gastrointestinal Cancer Articles | Page 2

Pancreatic Ductal Carcinoma: Slow Progress for a Hard-to-Treat Cancer
Pancreatic ductal adenocarcinoma, which is considered incurable, accounts for more than 90% of pancreatic cancer cases.
Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.
No Reduction in HRQOL With Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Neoadjuvant chemoradiotherapy did not lower postoperative health-related quality of life compared with surgery alone for patients with esophageal or junctional cancer.
FGFR Inhibitor Tested in Hard-to-Treat GI Cancer
Given that few options are available for intrahepatic cholangiocarcinoma, investigators are excited about a phase III trial of the multikinase inhibitor derazantinib as a second-line treatment for patients with inoperable or advanced disease.
TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).
Efforts Continue to Optimize Immunotherapy in Gastric Cancer
David H. Ilson, MD, PhD, discusses practice-changing trials, the optimal available therapies, and how immunotherapy fits into the future treatment paradigm for gastric cancer.
Marshall Recaps Milestones in CRC Paradigm
John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.
Understanding the Implications of Mutational Status in Intrahepatic Cholangiocarcinoma
Jesper B. Andersen, MSc, PhD, discusses the findings of a study evaluating a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma. 
Novel Technology Emerging in GI Cancer Treatment Landscape
Christopher Crane, MD, discusses modern innovative techniques in GI cancers.
Novel Approaches May Push Pancreatic Cancer Treatment Forward
Eileen O’Reilly, MD, discusses novel therapeutic approaches for the treatment of patients with pancreatic cancer.
Publication Bottom Border
Border Publication
x